Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Expands Russian OTC Foothold Via J.B. Chemicals Portfolio Acquisition

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson expands its consumer health presence in Russia and other Eastern European markets with the acquisition of several OTC brands from J.B. Chemicals & Pharmaceuticals.

You may also be interested in...



J&J Cites Neutrogena Among 20 Product Launches Planned For 2015

CEO Alex Gorsky says “20 key product launches” are targeted for 2015, including extensions of the Neutrogena Hydro Boost skin-care and Listerine Healthy White mouthwash lines. Skin care propelled U.S. growth of 2.5% in J&J’s consumer-health business during the fourth quarter, the firm reported.

J&J Includes Listerine In 20 Consumer Product Launches Planned In 2015

CEO Alex Gorsky says “20 key product launches” are planned for 2015, including extensions for the Listerine Healthy White mouthwash Neutrogena Hydro Boost skin care lines. Analgesics and upper respiratory products drive global OTC sales growth in the fourth quarter.

J&J Includes Listerine In 20 Consumer Product Launches Planned In 2015

CEO Alex Gorsky says “20 key product launches” are planned for 2015, including extensions for the Listerine Healthy White mouthwash Neutrogena Hydro Boost skin care lines. Analgesics and upper respiratory products drive global OTC sales growth in the fourth quarter.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel